Inhibitors of dipeptidylpeptidase 4 (DPP4), an enzyme degrading GLP-1 (sitagliptin or vildagliptin) have also been shown to reduce serum liver enzyme levels and hepatic lipid accumulation in a NASH mouse model [56] or human NAFLD (or NASH) patients [57]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.